etoposide has been researched along with Graft vs Host Disease in 110 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (5.45) | 18.7374 |
| 1990's | 33 (30.00) | 18.2507 |
| 2000's | 36 (32.73) | 29.6817 |
| 2010's | 26 (23.64) | 24.3611 |
| 2020's | 9 (8.18) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Fan, S; Jiang, F; Liu, X; Liu, Z; Sun, Y; Xiao, J | 1 |
| Albert, MH; Bader, P; Basu, O; Beier, R; Burkhardt, B; Classen, CF; Claviez, A; Corbacioglu, S; Deubzer, HE; Eichinger, A; Glogova, E; Greil, J; Gruhn, B; Güngör, T; Kafa, K; Kühl, JS; Lang, P; Lange, BS; Meisel, R; Müller, I; Peters, C; Poetschger, U; Sauer, MG; Schlegel, PG; Schulz, A; Stachel, D; Strahm, B; Wawer, A | 1 |
| Adachi, H; Atsuta, Y; Doki, N; Hashimoto, S; Igarashi, A; Kaito, S; Kishida, Y; Kito, S; Kobayashi, T; Konishi, T; Konuma, R; Marumo, A; Mukae, J; Murofushi, KN; Nagata, A; Najima, Y; Noguchi, Y; Ogawa, H; Ohashi, K; Shimizu, H; Shingai, N; Toya, T; Wada, A; Yamada, Y | 1 |
| Dowling, M; Grigg, A; Janson, B; Khot, A; Siderov, J; Stewart, T; Xie, J | 1 |
| Imamura, M | 1 |
| Areco, K; Deus, DF; Maranhão, RC; Morikawa, AT; Oliveira, JSR; Rohr, SS; Tavoni, TM | 1 |
| Li, Z; Liu, W; Ma, H; Qin, M; Wang, T; Wei, A; Yang, Y; Zhang, L; Zhang, R; Zhao, X | 1 |
| Altmann, B; Banos, A; Bay, JO; Bilger, K; Bouabdallah, K; Braulke, F; Cartron, G; Damaj, G; de Leval, L; Delmer, A; Dreger, P; Dreyling, M; Friedrichs, B; Gaulard, P; Gisselbrecht, C; Glass, B; Gyan, E; Haenel, M; Jaccard, A; Keller, U; Kroschinsky, F; Lamy, T; Leclerc, M; Lindemann, W; Metzner, B; Milpied, N; Nickelsen, M; Poeschel, V; Reimer, P; Rosenwald, A; Roussel, M; Sanhes, L; Schmitz, N; Sibon, D; Tournilhac, O; Truemper, L; Viardot, A; Wagner, E; Wilhelm, M; Wulf, G; Ziepert, M | 1 |
| Bas, EG; Celen, S; Daloglu, H; Hazar, V; Kabakci, C; Karasu, GT; Pashayev, D; Pehlivan, B; Uygun, V; Yalcin, K; Yesilipek, A; Zhumatayev, S | 1 |
| Barnoud, D; Barthélémy, C; Béné, J; Bruno, B; Décaudin, B; Gautier, S; Lahoche, A; Odou, P; Petitpain, N; Pinçon, C; Simon, N; Vasseur, M | 1 |
| Aljurf, M; Apperley, J; Bloor, A; Chaganti, S; Czyz, A; Finke, J; Giebel, S; Labopin, M; Michallet, M; Mohty, M; Murray, M; Nagler, A; Orchard, K; Passweg, J; Reményi, P; Socié, G; Stuhler, G; Volin, L; Yakoub-Agha, I | 1 |
| Brown, PA; Chen, Y; Devidas, M; Esiashvili, N; Followill, DS; Grupp, SA; Hunger, SP; Kalapurakal, JA; Kessel, S; Laurie, F; Lu, X; Merchant, TE; Pulsipher, MA; Sathiaseelan, V; Schmitter, MK; Ulin, K; Wall, DA | 1 |
| Horwitz, S; Lunning, MA; Moskowitz, AJ | 1 |
| Madsen, HO; Minculescu, L; Sengeløv, H | 1 |
| Forman, SJ; Kim, JH; Liu, A; Palmer, J; Rosenthal, J; Schultheiss, TE; Stein, A; Tsai, N; Wong, JY | 1 |
| Barber, L; Clay, J; Devlia, V; Feliu, J; Mufti, G; Pagliuca, A; Raj, K; Shaw, B | 1 |
| Ahn, HS; Jang, IJ; Jang, MK; Kang, HJ; Kim, H; Kim, NH; Kim, S; Lee, JW; Lee, SH; Park, JD; Park, KD; Shin, HY; Song, SH; Yu, KS | 1 |
| Advani, RH; Agarwal-Hashmi, R; Donaldson, SS; Garfin, PM; Kharbanda, S; Link, MP; Luna-Fineman, S; Porteus, M; Weinberg, KI | 1 |
| Arnold, R; Ayuk, F; Beelen, D; Bethge, W; Bornhäuser, M; Gökbuget, N; Heinzelmann, M; Hölzer, D; Kobbe, G; Kröger, N; Martin, H; Meyer, RG; Pichlmeier, U; Schmid, C; Stelljes, M; Trenschel, R; Wolschke, C; Zander, A | 1 |
| Abugideiri, M; Butker, C; Butker, E; Chen, Z; Chiang, KY; Esiashvili, N; Haight, AE; Khan, MK; Kim, S; Nanda, RH; Zhang, C | 1 |
| Bojic, M; Greinix, H; Hermann, A; Jäger, U; Kalhs, P; Lamm, W; Leiner, M; Mitterbauer, M; Rabitsch, W; Schörgenhofer, C; Schulenburg, A; Sillaber, C; Skrabs, K; Sperr, WR; Wohlfarth, P | 1 |
| Lai, W; Wang, J; Wang, Y; Wang, Z; Wu, L; Zhang, J | 1 |
| Al Malki, MM; Aldoss, I; Ali, H; Aribi, A; Farol, L; Forman, SJ; Karanes, C; Khaled, S; Liu, A; Marcucci, G; Nakamura, R; O'Donnell, M; Palmer, J; Parker, P; Pawlowska, A; Pullarkat, V; Radany, E; Rosenthal, J; Sahebi, F; Salhotra, A; Sanchez, JF; Schultheiss, T; Snyder, D; Spielberger, R; Stein, A; Thomas, SH; Tsai, NC; Wong, J | 1 |
| Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P | 1 |
| Forman, SJ; Karanes, C; Kogut, N; Krishnan, AY; Nademanee, A; Nakamura, R; O'Donnell, M; Palmer, JM; Parker, P; Pullarkat, V; Rodriguez, R; Rosenthal, J; Senitzer, D; Shayani, S; Smith, E; Snyder, D | 1 |
| Grigg, AP; Hoyt, R; Ritchie, DS; Szer, J; Wirth, A | 1 |
| Chao, NJ; Chino, JP; Craciunescu, O; Folz, RJ; Horwitz, ME; Kelsey, CR; Marks, LB; Rizzieri, DA; Steffey, B | 1 |
| Bredeson, C; Ewell, M; Goodman, SA; Horowitz, MM; Kahl, BS; Laport, GG; Negrin, RS; Tomblyn, MR; Vose, JM | 1 |
| Cassuto, JP; Cluzeau, T; De Matteis, M; Gratecos, N; Mannone, L; Mounier, N; Raynaud, S; Sirvent, A; Thyss, A; Ticchioni, M | 1 |
| Hägglund, H; Karbach, H; Klimkowska, M; Machaczka, M; Nahi, H | 1 |
| Delioukina, M; Forman, SJ; Gaal, K; Kogut, N; Nademanee, A; O'Donnell, M; Palmer, JM; Popplewell, L; Senitzer, D; Thomas, S; Tsai, NC; Zain, J | 1 |
| Shigematsu, A | 1 |
| Aurlien, E; Baggerød, E; Bishop, MR; Brinch, L; Dybedal, I; Egeland, T; Fløisand, Y; Fosså, A; Fowler, DH; Gedde-Dahl, T; Heldal, D; Holte, H; Kolstad, A; Kvalheim, G; Lauritzsen, GF; Lehne, G; Tjønnfjord, GE; Torfoss, D | 1 |
| Casini, M; Cavattoni, IM; Cortelazzo, S; Deola, S; Farsad, M; Mian, M; Pescosta, N | 1 |
| Bauer, K; Engert, A; Hübel, K; Monsef, I; Rancea, M; Skoetz, N | 1 |
| Fan, ZP; Huang, F; Jiang, QL; Liu, QF; Meng, FY; Sun, J; Wei, YQ; Wu, MQ; Wu, XL; Xu, D; Yu, GP; Zhang, Y; Zhao, J | 1 |
| Byrne, J; Carter, GI; Craddock, CF; Cull, GM; Garg, M; Haynes, AP; Lui Yin, JA; Lush, RJ; Mahendra, P; Mufti, G; Pagliuca, A; Parker, JE; Potter, MN; Prentice, HG; Russell, NH | 1 |
| Cavenagh, J; Chopra, R; Clark, FJ; Culligan, D; Davies, A; Fuller, S; Hunt, L; Hunter, A; Littlewood, T; Lush, R; Marks, DI; Marsh, J; Milligan, DW; Parker, A; Schey, S; Smith, GM; Towlson, K; Vandenberghe, E; Williams, CD; Yin, J | 1 |
| Andersson, PO; Brune, M; Gustavsson, B; Stockelberg, D; Wadenvik, H; Wernstedt, P | 1 |
| Ballen, K; Becker, PS; Clark, Y; Emmons, RV; Levy, W; Liu, Q; Rossi, HA; Westervelt, P | 1 |
| Au, WY; Chan, EC; Kwong, YL; Leung, AY; Liang, R; Lie, AK; Ooi, GC; Siu, LL | 1 |
| Dekker, AW; Mandigers, CM; Meijerink, JP; Raemaekers, JM; Schattenberg, AV; Verdonck, LF | 1 |
| Abrahams, L; du Toit, C; McDonald, A; Novitzky, N; Thomas, V | 1 |
| Asaka, M; Chiba, K; Hashino, S; Imamura, M; Izumiyama, K; Kahata, K; Kato, N; Kobayashi, S; Kondo, T; Miura, Y; Mori, A; Ota, S; Tanaka, J; Toubai, T; Toyoshima, N; Yonezumi, M | 1 |
| Andresen, S; Ball, E; Bolwell, B; Cook, D; Kalaycio, M; Kuczkowski, E; Pohlman, B; Rybicki, L; Sobecks, R | 1 |
| Avalos, BR; Blum, W; Bolwell, BJ; Byrd, JC; Copelan, E; Elder, PJ; Farag, SS; Kalaycio, M; Lin, T; Marcucci, G; Penza, S; Pohlman, B; Sobecks, R | 1 |
| Rao, PS | 1 |
| Filipovich, AH; Gadner, H; Henter, JI; Horne, A; Imashuku, S; Janka, G; Ladisch, S; Locatelli, F; Maarten Egeler, R; Montgomery, SM; Webb, D; Winiarski, J | 1 |
| Bader, P; Boppana, S; Dormann, S; Fisch, P; Goebel, H; Jung, A; Kontny, U; Niemeyer, C; Peters, A; Strahm, B; Werner, M | 1 |
| Al-Jefri, A; Al-Mahr, M; Al-Seraihi, A; Ayas, M; Belgaumi, A; El-Solh, H; Elhassan, I | 1 |
| Blume, KG; Horning, SJ; Johnston, LJ; Laport, GG; Law, LY; Lowsky, R; Negrin, RS; Shizuru, JA; Stockerl-Goldstein, KE; Wong, RM | 1 |
| Cantu-Rodríguez, O; Gomez-Almaguer, D; Gonzalez-Llano, O; Gutierrez-Aguirre, H; Herrera-Garza, J; Jaime-Pérez, J; Mancias-Guerra, C | 1 |
| Martin, PL; McLean, TW; White, MS | 1 |
| Doyle, JJ; Gassas, A; Saunders, EF; Sung, L | 1 |
| Chen, H; Han, W; Huang, XJ; Liu, DH; Liu, KY; Xu, LP | 1 |
| Arber, C; Bucher, C; Buser, AS; Ghielmini, M; Gratwohl, A; Halter, J; Heim, D; Lohri, A; Meyer-Monard, S; Passweg, JR; Stern, M; Stussi, G; Tichelli, A | 1 |
| Ades, L; Attal, M; Bernard, M; Blaise, D; Bordigoni, P; Bourhis, JH; Cassuto, JP; Chevalier, P; Deconinck, E; Facon, T; Garban, F; Ifrah, N; Kuentz, M; Lioure, B; Michallet, M; Milpied, N; Porcher, R; Renaud, M; Socié, G; Tabrizi, R; Tilly, H; Vernant, JP; Vigouroux, S | 1 |
| Chiba, S; Izutsu, K; Kako, S; Kanda, Y; Kurokawa, M; Motokura, T; Oshima, K; Sato, H | 1 |
| Byrne, JL; Das-Gupta, EP; Devereux, S; Gonzalez, J; Haynes, AP; Ho, A; Ingram, W; McMillan, A; Mufti, GJ; Pagliuca, A; Russell, NH; Shaw, BE | 1 |
| Asaka, M; Endo, T; Hashino, S; Imamura, M; Kahata, K; Koike, T; Kondo, T; Nishio, M; Obara, M; Onozawa, M; Ota, S; Shigematsu, A; Shiratori, S; Sugita, J; Takahata, M; Takeda, Y; Tanaka, J; Wakasa, K; Yamamoto, S | 1 |
| Bernstein, E; Brodsky, I; Bulova, S; Crilley, P; Marks, DI; Mullaney, R; Resnick, K; Styler, MJ; Topolsky, D | 1 |
| Amylon, MD; Blume, KG; Chao, NJ; Kusnierz-Glaz, C; Long, GD; Negrin, RS | 1 |
| Brown, RA; Collins, RH; Fay, JW; Greer, J; Herzig, GP; Herzig, RH; Lynch, JP; Pineiro, L; Stevens, D; Wolff, SN | 2 |
| Bourdin, S; Harousseau, JL; Le Tortorec, S; Mahe, B; Mahe, JM; Mechinaud-Lacroix, F; Milpied, N; Moreau, P; Rapp, MJ; Wu, DP | 1 |
| Ashihara, E; Fujita, N; Goto, H; Hirata, T; Inaba, T; Nakagawa, M; Okawa, K; Oku, N; Shimazaki, C; Yamagata, N | 1 |
| Chan, KW; Cole, CH; Davis, JE; Phillips, G; Pritchard, S; Rogers, PC | 1 |
| Ito, H; Kimura, Y; Nakamura, H; Nomura, N; Otaka, M; Sakai, N; Shirota, T; Suzuki, A; Toyama, K; Uchida, H | 1 |
| Amylon, MD; Chao, NJ; Long, GD; Nademanee, AP; Negrin, RS; O'Donnell, MR; Parker, PM; Smith, EP; Snyder, DS; Stein, AS | 1 |
| Amylon, MD; Chao, NJ; Long, GD; Nademanee, AP; Negrin, RS; O'Donnell, MR; Schmidt, GM; Snyder, DS; Stein, AS; Taguchi, J | 1 |
| Tutschka, PJ | 1 |
| Anderson, JR; Armitage, JO; Bierman, P; Bishop, MR; Cowles, MK; Kessinger, A; Martin-Algarra, S; Reed, E; Tarantolo, S; Vose, JM | 1 |
| Bettoni, C; Daszkiewicz, P; Ebell, W; Głuszak, B; Kaczmarek-Kanold, M; Lange, A; Malicki, J; Suchnicki, K; Wachowiak, J | 1 |
| Asaka, M; Hashino, S; Imamura, M; Kasai, M; Kobayashi, S; Noto, S; Sakurada, K; Tanaka, J | 1 |
| Avalos, BR; Bechtel, TP; Belt, PS; Copelan, EA; Elder, PJ; Ezzone, SA; Hehmeyer, DM; Penza, SL; Scholl, MD | 1 |
| Baker, KS; DeLaat, CA; Filipovich, AH; Gross, TG; Harris, R; Loechelt, B; Shapiro, RS; Steinbuch, M | 1 |
| Asaka, M; Hashino, S; Imamura, M; Kasai, M; Kobayashi, S; Sakurada, K; Tanaka, J | 1 |
| Amylon, MD; Blume, KG; Chao, NJ; Forman, SJ; Hoppe, RT; Hu, WW; Long, GD; Nademanee, AP; Negrin, RS; Niland, J; Reichardt, VL; Snyder, DS; Stockerl-Goldstein, KE; Vora, N; Wong, R | 1 |
| Harvell, JD; Hashem, C; White, WL; Williford, PL | 1 |
| Berger, C; Braumann, D; de Witt, M; Erttmann, R; Fiedler, W; Grimm, J; Horstmann, M; Hossfeld, KD; Illiger, HJ; Kabisch, H; Kröger, N; Krüger, W; Kuse, R; Schönrock, P; Stockshläder, M; Weh, HJ; Zander, AR; Zeller, W | 1 |
| Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Caldera, D; Colombo, A; Malcovati, L; Martinelli, G; Pagnucco, G; Salvaneschi, L | 1 |
| Ahmed, T; Baskind, P; Beer, M; Chiao, JW; Feldman, E; Goff, H; Seiter, K; Stein, M | 1 |
| Abboud, CN; Constine, LS; DiPersio, JF; Duerst, RE; Horan, JT; Liesveld, JL; Passarell, JA; Raubertas, RF; Senf, ES; Zwetsch, LM | 1 |
| Appelbaum, FR | 1 |
| Barnett, MJ; Connors, JM; Gascoyne, RD; Hogge, DE; Klingemann, HG; Nantel, SH; Nevill, TJ; Phillips, GL; Reece, DE; Shepherd, JD; Sutherland, HJ; Toze, CL; Voss, NJ | 1 |
| Daugherty, CK; Hallahan, DE; Laport, GF; Larson, RA; Sobecks, RM; Wagner, ND | 1 |
| Braumann, D; Colberg, H; del Valle, F; Erttmann, R; Fiedler, W; Finkenstein, F; Holstein, K; Kabisch, H; Kröger, N; Krüger, W; Kuse, R; Mayer, U; Metzner, B; Renges, H; Sonnen, R; Sonnenberg, S; Stute, N; Zabelina, T; Zander, AR | 1 |
| Kelleher, JF; King, AK; Konefal, S; Monteleone, PM; Steele, DA | 1 |
| Kim, S; Kim, SH; Kim, WK; Lee, JH; Lee, JS; Lee, KH; Seol, M | 1 |
| Arcese, W; Cerretti, R; De Felice, L; Donato, V; Fenu, S; Guglielmi, C; Iori, A; Laurenti, L; Mengarelli, A; Micozzi, A; Romano, A; Torromeo, C | 1 |
| Baker, KS; Nagarajan, R; Neglia, J; Ramsay, N | 1 |
| Hara, T; Hattori, H; Ishii, S; Matsuzaki, A; Suminoe, A | 1 |
| Döhner, H; Gabler, A; Haas, R; Hartmann, F; Hensel, M; Ho, AD; Jung, W; Schlenk, RF; Trümper, L; Weber-Nordt, R | 1 |
| Ash, RC; Beatty, PA; Lundberg, JH; Weissman, DE | 1 |
| Bocheńska, J; Glejzer, O; Jaźwiec, B; Klimczak, A; Kołodziej, J; Pacuszko, T; Sedzimirska, M; Tomaszewska-Toporska, B; Tomeczko, J; Was, A | 1 |
| Appelbaum, FR; Bensinger, WI; Buckner, CD; Clift, RA; Deeg, HJ; Petersen, FB; Sanders, JE; Storb, R; Sullivan, KM; Witherspoon, RP | 1 |
| Ambros, P; Emminger, W; Emminger-Schmidmeier, W; Ferstl, G; Fink, FM; Haas, OA; Höcker, P; Mann, G; Peters, C; Urban, C | 1 |
| Bierman, PJ; Dennison, JD; Gordon, BG; Klassen, L; Kumar, PP; McGuire, TR; Reed, EC; Sanger, WG; Vaughan, WP; Warkentin, PI | 1 |
| Bender-Götze, C; Dopfer, R; Ebell, W; Ehninger, G; Friedrich, W; Gadner, H; Henze, G; Klingebiel, T; Peters, C; Riehm, H | 1 |
| Emminger, W; Emminger-Schmidmeier, W; Gadner, H; Peters, C | 1 |
| Butturini, A; Gale, RP; Reizenstein, P | 1 |
| Dölken, G; Fauser, AA; Herbst, EW; Kreisel, W | 1 |
| Appelbaum, FR; Buckner, CD; Durnam, D; Epstein, C; Hill, R; Nemunaitis, J; Singer, JW; Storb, R; Thomas, ED | 1 |
| Anasetti, C; Appelbaum, FR; Beatty, P; Doney, K; Martin, P; Pepe, M; Stewart, P; Storb, R; Sullivan, KM; Witherspoon, R | 1 |
| Colvin, OM; Santos, GW | 1 |
| Jones, RJ; Santos, GW | 1 |
| Cahill, R; Cottler-Fox, M; Deeg, HJ; Greenspan, A; Lynch, M; Spitzer, TR; Torrisi, J | 1 |
| Brix, F; Gassmann, W; Heit, W; Hertenstein, B; Holthuis, JJ; Johannson, W; Rister, M; Schaub, J; Schmitz, N; Suttorp, M | 1 |
| Blume, KG; Doroshow, JH; Fahey, JL; Forman, SJ; Krance, RA; Metter, GE; Nademanee, AP; O'Donnell, MR; Schmidt, GM; Snyder, DS | 1 |
| Brix, F; Dühmke, E; Euler, HH; Gassmann, W; Gremmel, H; Hebbinghaus, D; Kayser, W; Schaub, J; Schmitz, N; Wüstemann, M | 1 |
12 review(s) available for etoposide and Graft vs Host Disease
| Article | Year |
|---|---|
Medium-dose etoposide, cyclophosphamide and total body irradiation conditioning potentiates anti-leukemia immunity in adults with acute lymphoblastic leukemia without aggravating graft-versus-host disease.
Topics: Adult; Cyclophosphamide; Etoposide; Graft vs Host Disease; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Whole-Body Irradiation | 2023 |
[Significance of intensified conditioning regimen for allogeneic hematopoietic stem cell transplantation for treatment of acute leukemias].
Topics: Acute Disease; Cyclophosphamide; Cytarabine; Etoposide; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Melphalan; Recurrence; Risk; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2011 |
Fourteenth biannual report of the Cochrane Haematological Malignancies Group--focus on autologous stem cell transplantation in hematological malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Colony-Stimulating Factors; Cyclophosphamide; Dacarbazine; Disseminated Intravascular Coagulation; Doxorubicin; Etoposide; Evidence-Based Medicine; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Prednisone; Procarbazine; Purpura, Thrombocytopenic, Idiopathic; Randomized Controlled Trials as Topic; Receptors, Thrombopoietin; Remission Induction; Transplantation, Autologous; Transplantation, Homologous; Vinblastine; Vincristine; Viral Vaccines | 2012 |
Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation.
Topics: Actuarial Analysis; Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cyclophosphamide; Etoposide; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome; Whole-Body Irradiation | 1994 |
Use of busulfan containing chemotherapy for conditioning patients with leukemia for bone marrow allografting.
Topics: Actuarial Analysis; Adult; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytokines; Etoposide; Graft vs Host Disease; Humans; Leukemia; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Syndrome; Treatment Outcome; Whole-Body Irradiation | 1993 |
Is there a best transplant conditioning regimen for acute myeloid leukemia?
Topics: Acute Disease; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Clinical Trials, Phase II as Topic; Cyclophosphamide; Disease-Free Survival; Etoposide; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppression Therapy; Leukemia, Myeloid; Randomized Controlled Trials as Topic; Thiotepa; Transplantation Conditioning; Whole-Body Irradiation | 2000 |
Bilateral breast relapse in acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Breast; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Graft vs Host Disease; Humans; Idarubicin; Immunologic Factors; Interleukin-2; Leukemia, Myeloid, Acute; Leukemic Infiltration; Radiotherapy, High-Energy; Recurrence; Salvage Therapy; Thioguanine; Transplantation Conditioning; Vidarabine | 2001 |
Successful treatment of refractory Langerhans cell histiocytosis with unrelated cord blood transplantation.
Topics: Bone Marrow; Cladribine; Combined Modality Therapy; Cyclosporine; Cytarabine; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Fetal Blood; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histiocytosis, Langerhans-Cell; Humans; Infant, Newborn; Mercaptopurine; Methotrexate; Methylprednisolone; Prednisone; Remission Induction; Transplantation, Homologous; Vinblastine | 2001 |
Unrelated cord blood transplantation for an infant with chemotherapy-resistant progressive Langerhans cell histiocytosis.
Topics: Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Drug Resistance; Drug Therapy, Combination; Etoposide; Fetal Blood; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histiocytosis, Langerhans-Cell; Humans; Infant; Male; Mercaptopurine; Methotrexate; Methylprednisolone; Mitoxantrone; Prednisolone; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Vincristine | 2001 |
[Allogeneic bone marrow transplantation in myeloid leukemia: chemical conditioning, clinical course and results].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Etoposide; Graft Enhancement, Immunologic; Graft vs Host Disease; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Transplantation, Homologous | 1992 |
Autotransplants in leukemia: current state, future progress.
Topics: Bone Marrow Transplantation; Cyclophosphamide; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation, Autologous; Twins, Monozygotic | 1991 |
Pharmacological purging of bone marrow with reference to autografting.
Topics: Adolescent; Adult; Animals; Bleomycin; Bone Marrow; Bone Marrow Transplantation; Cell Separation; Child; Child, Preschool; Clinical Trials as Topic; Cyclophosphamide; Drug Evaluation; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Lysophosphatidylcholines; Methylprednisolone; Neoplasms, Experimental; Phospholipid Ethers; Pyrimidinones; Transplantation, Autologous; Transplantation, Isogeneic | 1986 |
30 trial(s) available for etoposide and Graft vs Host Disease
| Article | Year |
|---|---|
A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL.
Topics: Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Graft vs Host Disease; Humans; Kaplan-Meier Estimate; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Myeloablative Agonists; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prospective Studies; Risk; Transplantation Conditioning; Transplantation, Autologous; Vincristine | 2021 |
Higher Reported Lung Dose Received During Total Body Irradiation for Allogeneic Hematopoietic Stem Cell Transplantation in Children With Acute Lymphoblastic Leukemia Is Associated With Inferior Survival: A Report from the Children's Oncology Group.
Topics: Adolescent; Analysis of Variance; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Dose Fractionation, Radiation; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Lung; Patient Positioning; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiation Dosage; Remission Induction; ROC Curve; Thiotepa; Transplantation Conditioning; Whole-Body Irradiation; Young Adult | 2019 |
Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Blast Crisis; Bone Marrow; Busulfan; Child; Cyclophosphamide; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphatic Irradiation; Melphalan; Middle Aged; Myelodysplastic Syndromes; Organ Sparing Treatments; Organs at Risk; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Radiotherapy Dosage; Recurrence; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2014 |
Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL).
Topics: Adolescent; Adult; Allografts; Busulfan; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Humans; Male; Middle Aged; Myeloablative Agonists; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Stem Cell Transplantation; Transplantation Conditioning | 2015 |
PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cisplatin; DNA, Viral; Epstein-Barr Virus Infections; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphohistiocytosis, Hemophagocytic; Male; Middle Aged; Polyethylene Glycols; Prednisone; Remission Induction; Salvage Therapy; Transplantation Conditioning; Treatment Outcome; Young Adult | 2016 |
Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia.
Topics: Acute Disease; Adolescent; Adult; Bone Marrow; Cyclophosphamide; Dose-Response Relationship, Radiation; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Lymphatic Irradiation; Male; Middle Aged; Recurrence; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Young Adult | 2017 |
A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.
Topics: Adolescent; Adult; Busulfan; Child; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Pilot Projects; Radiation Dosage; Siblings; Sirolimus; Survival Analysis; Tacrolimus; Thrombotic Microangiopathies; Tissue Donors; Transplantation Conditioning; Vidarabine; Young Adult | 2010 |
Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Living Donors; Lymphoma, Follicular; Male; Methotrexate; Middle Aged; Remission Induction; Rituximab; Salvage Therapy; Siblings; Tacrolimus; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2011 |
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisolone; Rituximab; Sirolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vincristine; Young Adult | 2012 |
Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
Topics: Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Blood Donors; Carmustine; Cytarabine; Disease Progression; Etoposide; Female; Graft Survival; Graft vs Host Disease; Humans; Immunosuppression Therapy; Lymphocyte Transfusion; Lymphoproliferative Disorders; Male; Melphalan; Middle Aged; Monitoring, Physiologic; Secondary Prevention; Stem Cell Transplantation; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2001 |
High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Blood Platelets; Carmustine; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infections; Liver Diseases; Lung Diseases; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutrophils; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2003 |
Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Remission Induction; Survival Analysis; Treatment Outcome | 2004 |
CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Carmustine; CD8-Positive T-Lymphocytes; Cyclophosphamide; Etoposide; Female; Graft Survival; Graft vs Host Disease; Histocompatibility; Histocompatibility Testing; Humans; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Middle Aged; Salvage Therapy; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2005 |
High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cause of Death; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2005 |
Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Haplotypes; Histocompatibility; HLA Antigens; Humans; Imatinib Mesylate; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia; Lymphocyte Transfusion; Male; Methotrexate; Mitoxantrone; Pancytopenia; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Recurrence; Remission Induction; Salvage Therapy; Tissue Donors; Treatment Outcome | 2007 |
High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma; Male; Melphalan; Remission Induction; Transplantation Conditioning; Transplantation, Homologous | 2007 |
Role of etoposide (VP-16) in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation.
Topics: Actuarial Analysis; Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cyclophosphamide; Etoposide; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome; Whole-Body Irradiation | 1994 |
High-dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: a study by the North American Marrow Transplant Group.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid; Male; Middle Aged; Salvage Therapy; Survival Analysis; Treatment Outcome; United States; Whole-Body Irradiation | 1995 |
Fractionated total-body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 94 patients with chronic myelogenous leukemia in chronic phase.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Cause of Death; Child; Chromosome Aberrations; Chromosome Disorders; Cyclosporine; Cytogenetics; Drug Therapy, Combination; Etoposide; Female; Graft vs Host Disease; Humans; Immunosuppression Therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Methylprednisolone; Middle Aged; Recurrence; Survival Rate; Whole-Body Irradiation | 1994 |
Can busulfan replace fractionated total body irradiation as conditioning regimen for allogeneic bone marrow transplantation in children with acute lymphoblastic leukemia.
Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Graft vs Host Disease; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Survival Rate; Whole-Body Irradiation | 1995 |
High-dose etoposide, cyclophosphamide and total body irradiation with allogeneic bone marrow transplantation for resistant acute myeloid leukemia: a study by the North American Marrow Transplant Group.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Graft vs Host Disease; Humans; Leukemia, Myeloid; Middle Aged; Prognosis; Whole-Body Irradiation | 1996 |
Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Male; Middle Aged; Whole-Body Irradiation | 1997 |
High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Male; Methotrexate; Methylprednisolone; Middle Aged; Remission Induction; Time Factors; Transplantation, Homologous | 1997 |
Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Grouping and Crossmatching; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Evaluation; Drug-Related Side Effects and Adverse Reactions; Etoposide; Graft Survival; Graft vs Host Disease; Humans; Infant; Leukemia; Myeloablative Agonists; Nuclear Family; Recurrence; Stomatitis; Survival Rate; Transplantation, Homologous; Whole-Body Irradiation | 2000 |
Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hemorrhage; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Transfusion; Lung; Lymphoma, Non-Hodgkin; Male; Middle Aged; Platelet Transfusion; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2000 |
Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
Topics: Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |
Etoposide, cyclophosphamide and fractionated total body irradiation as a preparative regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cyclophosphamide; Etoposide; Graft vs Host Disease; Humans; Leukemia; Lymphoma; Middle Aged; Transplantation, Autologous; Transplantation, Homologous; Whole-Body Irradiation | 1992 |
Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Daunorubicin; Etoposide; Follow-Up Studies; Graft vs Host Disease; Humans; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Time Factors; Transplantation, Homologous; Vincristine; Whole-Body Irradiation | 1991 |
What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants?
Topics: Acute Disease; Anemia, Aplastic; Bone Marrow Transplantation; Chronic Disease; Clinical Trials as Topic; Cyclophosphamide; Cyclosporins; Etoposide; Female; Follow-Up Studies; Graft vs Host Disease; Histocompatibility Testing; Humans; Immunosuppression Therapy; Leukemia; Male; Methotrexate; Myelodysplastic Syndromes; Prednisone; Random Allocation; Risk Factors; Whole-Body Irradiation | 1990 |
Pharmacological purging of bone marrow with reference to autografting.
Topics: Adolescent; Adult; Animals; Bleomycin; Bone Marrow; Bone Marrow Transplantation; Cell Separation; Child; Child, Preschool; Clinical Trials as Topic; Cyclophosphamide; Drug Evaluation; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cells; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Lysophosphatidylcholines; Methylprednisolone; Neoplasms, Experimental; Phospholipid Ethers; Pyrimidinones; Transplantation, Autologous; Transplantation, Isogeneic | 1986 |
70 other study(ies) available for etoposide and Graft vs Host Disease
| Article | Year |
|---|---|
Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation with Cocktail Conditioning Regimen for the Treatment of Pediatric Patients with Chronic Active Epstein-Barr Virus: A Retrospective Observational Study.
Topics: Antilymphocyte Serum; Busulfan; Child; Cyclophosphamide; Cytarabine; Epstein-Barr Virus Infections; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Herpesvirus 4, Human; Humans; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous | 2022 |
Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial.
Topics: Busulfan; Child; Cyclophosphamide; Etoposide; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Neoplasms; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2022 |
Outcomes of allogeneic haematopoietic stem cell transplantation with intensity-modulated total body irradiation by helical tomotherapy: a 2-year prospective follow-up study.
Topics: Cyclophosphamide; Cytarabine; Etoposide; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Neoplasm Recurrence, Local; Prospective Studies; Radiotherapy, Intensity-Modulated; Retrospective Studies; Transplantation Conditioning; Whole-Body Irradiation | 2022 |
Acute kidney injury in patients receiving high-dose etoposide phosphate as conditioning prior to hematopoietic stem cell transplantation in hematologic malignancies may be associated with elevated body mass index.
Topics: Acute Kidney Injury; Body Mass Index; Etoposide; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning | 2023 |
Novel Approach for Bone Marrow Transplantation Conditioning in Acute Myelogenous Leukemia not Responding to the Induction Therapy Using Etoposide Carried in Lipid Core Nanoparticles: A Pilot Clinical Study.
Topics: Adult; Aged; Bone Marrow; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Lipids; Middle Aged; Nanoparticles; Pilot Projects; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation; Young Adult | 2020 |
Treatment of pediatric primary hemophagocytic lymphohistiocytosis with the HLH-94/2004 regimens and hematopoietic stem cell transplantation in China.
Topics: Child; Child, Preschool; China; Combined Modality Therapy; Cyclosporine; Disease-Free Survival; Doxorubicin; Drug Therapy, Combination; Etoposide; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Kaplan-Meier Estimate; Lymphohistiocytosis, Hemophagocytic; Methylprednisolone; Prognosis; Remission Induction; Retrospective Studies; Transplantation Conditioning; Treatment Outcome | 2020 |
Comparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Organophosphorus Compounds; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2021 |
Acute kidney injury after high dose etoposide phosphate: A retrospective study in children receiving an allogeneic hematopoetic stem cell transplantation.
Topics: Acute Kidney Injury; Antineoplastic Agents; Child; Etoposide; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Organophosphorus Compounds; Prognosis; Retrospective Studies; Survival Rate; Transplantation Conditioning | 2018 |
Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph-negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society
Topics: Adult; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation | 2018 |
Strategies for relapsed peripheral T-cell lymphoma: the tail that wags the curve.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Depsipeptides; Doxorubicin; Etoposide; Female; Graft vs Host Disease; Humans; Induction Chemotherapy; Lymphoma, T-Cell, Peripheral; Multimodal Imaging; Patient Selection; Positron-Emission Tomography; Prednisone; Recurrence; Severity of Illness Index; Stem Cell Transplantation; Tomography, X-Ray Computed; Transplantation, Homologous; Vincristine | 2013 |
T-cell chimerism is valuable in predicting early mortality in steroid-resistant acute graft-versus-host disease after myeloablative allogeneic cell transplantation.
Topics: Acute Disease; Adolescent; Adult; Allografts; Cyclophosphamide; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Organophosphorus Compounds; Prednisolone; T-Lymphocyte Subsets; Transplantation Chimera; Transplantation Conditioning; Whole-Body Irradiation; Young Adult | 2014 |
Transplant-acquired food allergy (TAFA) following cord blood stem cell transplantation in two adult patients with haematological malignancies.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cytarabine; Daunorubicin; Drug Therapy, Combination; Egg Hypersensitivity; Etoposide; Female; Food Hypersensitivity; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunosuppressive Agents; Intestinal Diseases; Leukemia, Myeloid, Acute; Liver Diseases; Male; Middle Aged; Nut Hypersensitivity; Seafood; Tacrolimus; Transplantation Conditioning; Vidarabine | 2014 |
Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients.
Topics: Child; Child, Preschool; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Injections, Intravenous; Male; Myeloablative Agonists; Neutrophils; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Siblings; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine; Young Adult | 2015 |
Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory Hodgkin lymphoma: twenty years experience at a single institution.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Carmustine; Child; Cyclophosphamide; Etoposide; Female; Gamma Rays; Graft vs Host Disease; Hodgkin Disease; Humans; Male; Myeloablative Agonists; Neoplasm Recurrence, Local; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2015 |
Factors Influencing Pulmonary Toxicity in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in the Setting of Total Body Irradiation-Based Myeloablative Conditioning.
Topics: Acute Disease; Adolescent; Allografts; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Incidence; Infant; Lung; Male; Pneumonia; Radiotherapy Dosage; Transplantation Conditioning; Whole-Body Irradiation; Young Adult | 2016 |
Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft vs Host Disease; Hodgkin Disease; Humans; Male; Melphalan; Recurrence; Transplantation Conditioning; Young Adult | 2016 |
A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aspergillus; Busulfan; China; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Idarubicin; Immunosuppressive Agents; Leukemia; Leukemia, Myeloid, Acute; Male; Methylprednisolone; Mucositis; Pneumonia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Premedication; Retrospective Studies; Risk Factors; Semustine; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2009 |
Etoposide induces more severe mucositis than CY when added to TBI as conditioning in allograft recipients receiving CsA and MTX.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Cyclophosphamide; Cyclosporine; Drug Therapy, Combination; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia; Male; Methotrexate; Middle Aged; Mucositis; Retrospective Studies; Severity of Illness Index; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation; Young Adult | 2010 |
Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: an assessment of risk factors.
Topics: Acute Disease; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematologic Neoplasms; Humans; Lung; Male; Melphalan; Middle Aged; Pneumonia; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2011 |
New sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem-cell transplantation in very high-risk acute myeloid leukemia.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Thiotepa; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
Successful treatment of recurrent malignancy-associated hemophagocytic lymphohistiocytosis with a modified HLH-94 immunochemotherapy and allogeneic stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Dexamethasone; Drug Therapy, Combination; Etoposide; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Lymphohistiocytosis, Hemophagocytic; Lymphoma, Large-Cell, Anaplastic; Mitoxantrone; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Stem Cell Transplantation; Transplantation, Homologous; Young Adult | 2012 |
Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosphamide; Disease Progression; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Radiotherapy; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2011 |
Bendamustine salvage for the treatment of relapsed Hodgkin's lymphoma after allogeneic bone marrow transplantation.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bleomycin; Bone Marrow Transplantation; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Deoxycytidine; Doxorubicin; Etoposide; Fatal Outcome; Female; Gemcitabine; Graft vs Host Disease; Hodgkin Disease; Humans; Ifosfamide; Male; Nitrogen Mustard Compounds; Prednisolone; Prednisone; Procarbazine; Recurrence; Reoperation; Rituximab; Salvage Therapy; Transplantation, Autologous; Transplantation, Homologous; Vinblastine; Vincristine; Vinorelbine; Young Adult | 2013 |
Allo-HSCT for acute leukemia of ambiguous lineage in adults: the comparison between standard conditioning and intensified conditioning regimens.
Topics: Adolescent; Adult; Busulfan; Child; Cyclophosphamide; Cytarabine; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Biphenotypic, Acute; Male; Middle Aged; Retrospective Studies; Standard of Care; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation; Young Adult | 2013 |
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclosporine; Cytarabine; Data Collection; Etoposide; Female; Follow-Up Studies; Graft Enhancement, Immunologic; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
Topics: Adult; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Betamethasone; Biomarkers, Tumor; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Imatinib Mesylate; Immunosuppressive Agents; Mitoxantrone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Homologous; Vincristine | 2002 |
Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Neutropenia; Recurrence; Remission Induction; Thrombocytopenia; Tomography, X-Ray Computed; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2003 |
Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Immunophenotyping; Lymphocyte Depletion; Lymphocyte Transfusion; Lymphoma, Non-Hodgkin; Male; Mechlorethamine; Methotrexate; Middle Aged; Peripheral Blood Stem Cell Transplantation; Polymerase Chain Reaction; Prednisolone; Prednisone; Procarbazine; Radiotherapy, Adjuvant; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Tissue Donors; Transplantation, Homologous; Treatment Outcome; Vincristine | 2003 |
Efficacy of etoposide, cyclophosphamide, and total body irradiation in allogeneic bone marrow transplantation for adult patients with hematological malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Bone Marrow Transplantation; Cause of Death; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Middle Aged; Remission Induction; Retrospective Studies; Safety; Survival Rate; Transplantation Conditioning; Treatment Outcome; Whole-Body Irradiation | 2004 |
Nephrotic syndrome in patients with peripheral blood stem cell transplant.
Topics: Acute Kidney Injury; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytomegalovirus Infections; Etoposide; Glomerulonephritis, Membranous; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Prednisone; Rituximab; Sepsis; Staphylococcal Infections; Tacrolimus; Transplantation Conditioning | 2005 |
Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cyclosporine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histiocytosis, Non-Langerhans-Cell; Humans; Immunophenotyping; Infant; Male; Methotrexate; Odds Ratio; Regression Analysis; Reoperation; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2005 |
Post-transplantation lymphoproliferative disorder of recipient origin in a boy with acute T-cell leukemia with detection of B-cell clonality 3 months before stem cell transplantation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; B-Lymphocytes; Child; Clone Cells; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Cytarabine; Daunorubicin; Dexamethasone; Epstein-Barr Virus Infections; Etoposide; Fatal Outcome; Glucocorticoids; Graft vs Host Disease; Herpesvirus 4, Human; Humans; Immunosuppressive Agents; Leukemia-Lymphoma, Adult T-Cell; Lymphocyte Transfusion; Lymphoproliferative Disorders; Male; Postoperative Complications; Prednisolone; Rituximab; Time Factors; Transplantation Chimera; Transplantation Conditioning; Vincristine; Virus Activation; Whole-Body Irradiation | 2005 |
The outcome of children with acute myeloid leukemia (AML) post-allogeneic stem cell transplantation (SCT) is not improved by the addition of etoposide to the conditioning regimen.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Neoplasms, Second Primary; Recurrence; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2006 |
High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cause of Death; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2006 |
Successful father-to-son stem cell transplantation in a child with hemophagocytic lymphohistiocytosis using a reduced-intensity conditioning regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Etoposide; Family; Graft vs Host Disease; Humans; Infant; Lymphohistiocytosis, Hemophagocytic; Magnetic Resonance Imaging; Male; Melphalan; Methotrexate; Stem Cell Transplantation; Transplantation Conditioning; Vidarabine | 2006 |
Acute myelogenous leukemia associated with Ollier disease.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 21; Cytarabine; Daunorubicin; Enchondromatosis; Etoposide; Gemtuzumab; Graft vs Host Disease; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplastic Syndromes, Hereditary; Translocation, Genetic | 2008 |
Comparative outcome of hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia following cyclophosphamide and total body irradiation or VP16 and total body irradiation conditioning regimens.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Transplantation Conditioning; Whole-Body Irradiation | 2006 |
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
Topics: Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Data Collection; Disease-Free Survival; Etoposide; Female; France; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2007 |
Regression of the tumor after withdrawal of cyclosporine in relapsed extranodal natural killer/T cell lymphoma following allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cryptogenic Organizing Pneumonia; Cyclophosphamide; Cyclosporine; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunosuppressive Agents; Lymphoma, T-Cell, Peripheral; Methotrexate; Neoplasm Recurrence, Local; Palatal Neoplasms; Remission Induction; Salvage Therapy; Transplantation, Homologous; Vincristine | 2007 |
Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma.
Topics: Acute Disease; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Retrospective Studies; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome | 2008 |
Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Cyclophosphamide; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2008 |
Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Humans; Leukemia; Lung; Lymphoma; Male; Middle Aged; Recurrence; Skin; Survival Rate; Transplantation, Autologous; Transplantation, Homologous | 1995 |
Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Recurrence; Time Factors; Transplantation, Homologous; Whole-Body Irradiation | 1994 |
Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation: two-color flow cytometric analysis.
Topics: Acute Disease; Adolescent; Adult; Blood Component Transfusion; Busulfan; Combined Modality Therapy; Etoposide; Female; Flow Cytometry; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Leukemia, Myeloid; Leukocyte Count; Leukopenia; Lymphocyte Subsets; Lymphoma; Male; Middle Aged; Nitrosourea Compounds; Platelet Count; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1994 |
Intensive conditioning regimen for bone marrow transplantation in children with high-risk haematological malignancies.
Topics: Adolescent; Bacterial Infections; Bone Marrow Transplantation; Child; Child, Preschool; Cohort Studies; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Humans; Infant; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy Dosage; Remission Induction; Stomatitis; Survival Rate; Whole-Body Irradiation | 1994 |
Successful bone marrow transplant for a patient with T-lymphoblastic lymphoma in second remission preconditioned by total-body irradiation plus melphalan and etoposide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclosporine; Etoposide; Graft vs Host Disease; Humans; Male; Melphalan; Methotrexate; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Whole-Body Irradiation | 1994 |
Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytomegalovirus Infections; Etoposide; Female; Graft vs Host Disease; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Whole-Body Irradiation | 1993 |
Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
Topics: Adult; Aged; Bone Marrow Transplantation; Cyclophosphamide; Etoposide; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Histocompatibility; Humans; Leukemia; Male; Methotrexate; Middle Aged; Recombinant Proteins; Recurrence; Survival Rate; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 1995 |
Cytokine network in peripheral blood mononuclear cells after allogeneic bone marrow transplantation.
Topics: Bone Marrow Transplantation; Cyclophosphamide; Cyclosporine; Cytokines; Etoposide; Gene Expression; Graft vs Host Disease; Histocompatibility Testing; Humans; Immunosuppressive Agents; Interleukins; Lymphocytes; Methotrexate; Polymerase Chain Reaction; RNA, Messenger; Transplantation, Homologous; Whole-Body Irradiation | 1996 |
Influence of graft-versus-host disease on outcome following allogeneic transplantation with radiation-free preparative therapy in patients with advanced leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Graft vs Host Disease; Humans; Leukemia; Treatment Outcome | 1996 |
Successful correction of hemophagocytic lymphohistiocytosis with related or unrelated bone marrow transplantation.
Topics: Adrenal Cortex Hormones; Bone Marrow Transplantation; Child, Preschool; Combined Modality Therapy; Cyclosporine; Etoposide; Female; Graft vs Host Disease; Histiocytosis, Non-Langerhans-Cell; Humans; Immunosuppressive Agents; Infant; Injections, Spinal; Killer Cells, Natural; Male; Methotrexate; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 1997 |
Low levels of serum soluble c-kit relates to delayed engraftment after bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Bone Marrow Transplantation; Cyclophosphamide; Etoposide; Graft Rejection; Graft vs Host Disease; Humans; Leukemia; Lymphoma; Proto-Oncogene Proteins c-kit; Transplantation Conditioning; Whole-Body Irradiation | 1997 |
Grover's-like disease in the setting of bone marrow transplantation and autologous peripheral blood stem cell infusion.
Topics: Acantholysis; Adult; Bone Marrow Transplantation; Diagnosis, Differential; Drug-Related Side Effects and Adverse Reactions; Etoposide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Pemphigus | 1998 |
Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Etoposide; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Mitoxantrone; Recurrence; Time Factors; Tissue Donors; Transplantation Chimera; Transplantation, Homologous | 1999 |
Cyclosporine-induced autologous graft-versus-host disease in patients with acute myeloid leukemia undergoing non-myeloablative chemotherapy without progenitor cell reinfusion.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cyclophosphamide; Cyclosporine; Etoposide; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Interferon-gamma; Killer Cells, Natural; Leukemia, Myeloid, Acute; Male; Middle Aged; Skin; T-Lymphocyte Subsets | 1999 |
A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of advanced hematologic malignancies.
Topics: Adult; Blood Platelets; Cohort Studies; Combined Modality Therapy; Etoposide; Female; Graft Survival; Graft vs Host Disease; Heart Failure; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Liver; Lung; Lung Diseases; Male; Middle Aged; Mouth Mucosa; Neutrophils; Recurrence; Stomatitis; Survival; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2000 |
Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Evaluation; Etoposide; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid; Leukocytes; Male; Middle Aged; Recurrence; Survival Rate; Transplantation Conditioning; Treatment Outcome | 2000 |
Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukemia; Leukocyte Transfusion; Male; Recurrence; Survival Rate; Transplantation, Homologous | 2001 |
Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Infant; Leukemia; Life Tables; Male; Methylprednisolone; Middle Aged; Premedication; Retrospective Studies; Risk; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation | 2002 |
Treatment of recurrent metastatic medulloblastoma with intensive chemotherapy and allogeneic bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Bone Neoplasms; Brain Neoplasms; Combined Modality Therapy; Cyclophosphamide; Etoposide; Graft vs Host Disease; Humans; Lymphatic Metastasis; Male; Medulloblastoma; Prevalence; Remission Induction; Salvage Therapy; Transplantation, Homologous; Vincristine | 1992 |
Treatment of infant leukemia with busulfan, cyclophosphamide +/- etoposide and bone marrow transplantation.
Topics: Bone Marrow Transplantation; Busulfan; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Graft vs Host Disease; Hematopoiesis; Humans; Incidence; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1992 |
Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Humans; Immunosuppressive Agents; Incidence; Leukemia; Middle Aged; Time Factors; Transplantation, Homologous | 1991 |
Influence of immunosuppression on acute liver toxicity after intensified conditioning regimens for bone marrow transplantation in children.
Topics: Bone Marrow Transplantation; Busulfan; Child; Cyclosporins; Drug Therapy, Combination; Etoposide; Graft vs Host Disease; Humans; Immunosuppression Therapy; Leukemia; Liver; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Transplantation, Autologous; Whole-Body Irradiation | 1991 |
[Gastroenterologic findings in graft versus host disease after allogenic bone marrow transplantation].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Gastrointestinal Diseases; Graft vs Host Disease; Humans; Infant, Newborn; Intestinal Mucosa; Leukemia, Myeloid, Acute; Liver; Pregnancy; Pregnancy Complications, Neoplastic; Sigmoidoscopy | 1991 |
Use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation.
Topics: Adolescent; Adult; Aged; Bone Marrow; Bone Marrow Transplantation; Child; Child, Preschool; Colony-Stimulating Factors; Cyclophosphamide; Etoposide; Female; Graft Rejection; Graft vs Host Disease; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Substances; Hematopoiesis; Humans; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Transplantation, Autologous; Transplantation, Homologous | 1990 |
New conditioning regimens for high risk marrow transplants.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporins; Drug Evaluation; Etoposide; Graft vs Host Disease; Humans; Leukemia; Lymphoma; Middle Aged | 1989 |
Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Etoposide; Graft vs Host Disease; Humans; Leukemia; Middle Aged; Whole-Body Irradiation | 1989 |
Fractionated total body irradiation and high-dose VP 16-213 followed by allogeneic bone marrow transplantation in advanced leukemias.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Burkitt Lymphoma; Child; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Graft vs Host Disease; Humans; Leukemia; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Whole-Body Irradiation | 1988 |
Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies.
Topics: Acute Disease; Adult; Bone Marrow Transplantation; Child; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Evaluation; Etoposide; Graft vs Host Disease; Humans; Infant; Leukemia; Metabolic Clearance Rate; Whole-Body Irradiation | 1987 |
[Allogeneic bone marrow transplantation after fractionated whole body irradiation. Results at the Kiel transplantation center].
Topics: Acyclovir; Adolescent; Adult; Amphotericin B; Anemia, Aplastic; Bone Marrow Transplantation; Child; Cyclophosphamide; Etoposide; Female; Graft Survival; Graft vs Host Disease; Herpes Genitalis; HLA Antigens; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Male; Methotrexate; Middle Aged; Nystatin; Prednisolone; Tissue Donors; Whole-Body Irradiation | 1985 |